Optiscan Imaging Limited (OIL.AX)
Optiscan Imaging Limited operates in the Medical - Instruments & Supplies industry of the Healthcare sector, headquartered in Mulgrave, VIC, AU. The stock last traded at $0.18, down 5.13% on the session, giving a market capitalisation of $193.2M. Its beta of 0.10 implies it has historically moved less than the broad market.
Optiscan Imaging Limited specializes in the development and market introduction of confocal microscopy technology, applied across both clinical and pre-clinical settings in Australia, Germany, and other global regions. A notable offering is the FIVE2 (ViewnVivo) system, a compact confocal endomicroscope utilized for a broad range of research, including clinical, translational, and pre-clinical studies. Additionally, the company is actively developing the InVivage device, which is intended for use in cancer screening and surgical procedures. Established in 1994, Optiscan Imaging Limited maintains its headquarters in Mulgrave, Australia.
Optiscan Imaging Limited is most often compared with the following Healthcare names: